Education
About Us
Working with TipRanks
Follow Us
X4 Pharmaceuticals Inc (XFOR)
NASDAQ:XFOR
Mavorixafor
Hepatic Insufficiency
Phase I
Recruiting
A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function
Feb 27, 2025
―
Carbamazepine, Efavirenz, Mavorixafor
Healthy Participants
Phase I
Completed
Drug-Drug Interaction Potential of Mavorixafor
Feb 27, 2025
―
Mavorixafor
Neutropenia
Phase III
Recruiting
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
Sep 20, 2023
―
Ibrutinib, Mavorixafor
Waldenstrom's Macroglobulinemia
Phase I
Completed
A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4
Feb 12, 2020
―
Mavorixafor
Neutropenia
Phase I/II
Completed
A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders
Nov 04, 2019
―
Mavorixafor
Whim Syndrome
Phase III
Active Not Recruiting
Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
Jun 19, 2019
―
X4p-001
Whim Syndrome
Phase II
Completed
A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
Dec 20, 2016
―
Nivolumab, X4p-001
Clear Cell Renal Cell Carcinoma
Phase I/II
Terminated
Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma
Sep 30, 2016
―
Pembrolizumab, X4p-001
Melanoma
Phase I
Completed
X4P-001 and Pembrolizumab in Patients With Advanced Melanoma
Jul 01, 2016
―
X4p-001
Healthy
Phase I
Terminated
A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers
Feb 04, 2016
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does X4 Pharmaceuticals Inc (XFOR) have in its pipeline
XFOR is currently developing the following drugs: Mavorixafor, Carbamazepine, Efavirenz, Mavorixafor, Mavorixafor. These drug candidates are in various stages of clinical development as the company works toward FDA approval.